Having verified that CD133+ cancer cells are CSCs, we examined expression of TF and/or CD44 on CD133+ CSCs isolated from the human cancer lines, tumor xenografts and patients' tumor tissues to identify new biomarkers for CSCs. This evidence concerns the gene CD44 and neoplasm.